A single dose, two treatments (two cephalexin capsules brands), two sequences, cross-over design was used with a washout of 7 days between the two study periods. Treatment groups balanced with the same number of healthy volunteers who were randomly (in two strata: male and female) assigned to the study drug administration sequences.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
26
Single dose of 500 mg (One 500 mg capsule)
Single dose of 500 mg (Two 250 mg capsules)
Unnamed facility
Morelia, Michoacán, Mexico
Least square estimator of average maximum plasmatic concentration (log transformed)
Time frame: After two months
Least square estimator of area under the pharmacokinetic curve (log transformed)
Time frame: After two months
Time at which maximum concentration is reached
Time frame: After two months
Area under the pharmacokinetic curve from time=0 to last blood sample
Time frame: After two months
Clearance constant of plasmatic concentration of study drug
Time frame: After two months
Half life of plasmatic concentration of study drug
Time frame: After two months
Adverse events collection
Time frame: Up to six weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.